IETS – Instituto de Evaluación Tecnológica en Salud
Bogotá DC, Colombia
– Dr. Guillermo Sánchez, CEO, IETS
History and Structure
The Colombian agency of health technology assessment, Instituto de Evaluación Tecnológica en Salud (IETS), is a not-for-profit, public-private agency established in September 2012. Its members include the Colombian Ministry of Health and Social Protection, the National Institute of Food and Drug Monitoring (INVIMA), the Colombian National Institute of Health (INS), the Colombian Administrative Department of Science, Technology and Innovation (Colciencias), the Colombian Medical School Association (Ascofame) and the Colombian Association of Scientific Societies.
The activities of IETS include:
- Design, development, oversight and critical appraisal of clinical guidelines, economic evaluations and budget impact analyses commissioned by a wide range of bodies within the Colombian government
- Academic lectures and workshops on topics such as: evidence based medicine; systematic reviews and critical appraisal of medical and economic literature; development of clinical guidelines and economic evaluations of healthcare technologies; and participation and deliberation processes for informed decision making.
- Dissemination and implementation of evidence based clinical guidelines and other recommendations
IETS aims to stimulate and strengthen health technology research in Colombia, contribute to better patient care by supporting public health policy formulation, increase quality, efficiency, equity and sustainability of the Colombian healthcare system and improve equitable access to health care services and technologies.
How IETS Works
IETS produces health technology assessments, evidence-based clinical guidelines and protocols of drugs, medical devices, procedures and treatments to support policy makers and healthcare professionals decide what technologies are effective, offer the best quality and value for money and therefore should be financed with public funds.
Current Projects (A Selection):
- Ranibizumab for age-related macular degeneration
- Escitalopram for panic disorder, anxiety disorder and obsessive compulsive disorder
- Clinical practice guidelines for occupational safety and health
- Development of clinical pathways
- Provide advice on the design and implementation of health technology assessment agencies in middle-income countries
Description of population served: National
Population served (mil): 47
Current HTA budget (mil USD): 2 million annually
Permanent staff: 40
Ongoing TA projects: 40
CEO: Dr. Guillermo Sánchez
Contact person: Deputy Director of Health Technology Assessment
Instituto de Evaluación Tecnológica en Salud
Autorpista Norte 118-30. Oficina 201
Bogotá DC Colombia